NCT04375267View on ClinicalTrials.gov

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Clinical Trial, Phase INeuroendocrine TumorsThymomaMesothelioma
Interventions
DRUG

177Lu-DOTA-TATE + olaparib

177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib

Trial Locations (1)

41345

Dept of Oncology, Gothenburg

Sponsors
All Listed Sponsors
collaborator

Advanced Accelerator Applications

INDUSTRY

lead

Vastra Gotaland Region

OTHER_GOV